Tay-Sachs Disease Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Population of High-Risk Communities
- High Investment in R&D Activities, to Develop Treatment Methods
Challenges
- High Cost of Treatment
- Circulation of Generic Drugs in the Market
Tay-Sachs Disease Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
5.7% |
|
Base Year Market Size (2024) |
USD 2.42 billion |
|
Forecast Year Market Size (2037) |
USD 4.97 billion |
|
Regional Scope |
|
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of tay-sachs disease treatment is evaluated at USD 2.54 billion.
Tay-Sachs Disease Treatment Market size was over USD 2.42 billion in 2024 and is poised to exceed USD 4.97 billion by 2037, growing at over 5.7% CAGR during the forecast period i.e., between 2025-2037.
North America industry is estimated to account for largest revenue share by 2037, on the back of growing cases of Tay-Sachs disease in the region.
The major players in the market are Sio Gene Therapies Ltd, Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Amgen Inc. and others who manufacture drugs to treat the symptoms of Tay-Sachs disease.
